Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2023 Nice Insight Reports
Cell & Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking
Monoclonal Antibody & Recombinant Protein: 2023 Market Analysis, CDMO Pricing and Benchmarking
mRNA Vaccines & Therapeutics: 2023 Market Analysis, CDMO Pricing and Benchmarking
Sterile Drug Product: 2023 Market Analysis, CDMO Pricing and Benchmarking
Active Pharmaceutical Ingredients: 2023 Market Analysis, CDMO Pricing and Benchmarking
Antibody Drug Conjugates: 2023 Market Analysis, CDMO Pricing and Benchmarking
Contract Research Organizations: 2023 Market Analysis, Pricing and Benchmarking
Oral Solid Dosage: 2023 Market Analysis, CDMO Pricing and Benchmarking
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
ADC
27 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Biomanufacturing
New Name, Same Expertise: Goodwin Biotechnology is Becoming GBI!
PAO-11-022-CL-11
Opioid Conjugate Vaccines
Vaccines Present a Novel Strategy for Opioid Overdose Prevention
PAO-10-022-CL-07
ADCS
Improving the Therapeutic Index of ADCs with a Peptide Linker Technology
PAO-07-022-CL-01
Antibody-Drug Conjugates
Accelerating ADC Development with Advanced Payload Intermediates
PAO-06-21-CL-11
Antibody–Drug Conjugates
Preparing for the ADC Explosion with End-to-End Support
PAP-Q4-20-CL-014
Expansion
MilliporeSigma Announces $65 Million Antibody-Drug Conjugate Manufacturing Expansion
PR-M09-20-NI-14
Collaboration
AstraZeneca and Daiichi Sankyo Enter Collaboration to Develop and Commercialize New Antibody Drug Conjugate
PR-M07-20-NI-41
Antibody–Drug Conjugates
Linking Novel Medicines to Patients with Hard-to-Treat Cancers for Improved Quality of Life
PAP-Q2-20-CL-012
Licensing
Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs
PR-M02-20-NI-027
Antibody-Drug Conjugate
Fast-Tracking ADC Development and Commercialization
PAP-Q4-19-CL-003
Financing
Araris Biotech AG Closes Seed Financing Round of CHF 2.5 Million
PR-M08-19-NI-057
FDA Approval
Genetech’s Antibody–Drug Conjugate Receives FDA Approval
PAO-M06-19-NI-010
Antibody-Drug Conjugate
Integrating ADC Manufacturing for the Future
PAP-Q2-2019-CL-002
ADC
Speeding up ADC Development With the Right Partner Organization
PAP-Q2-2019-CL-001
Antibody-Drug Conjugates
Rapid Growth in the ADC Market Drives Strategic Partnership Interest
PAP-Q1-2019-CL-031
ADC
Ajinomoto Bio-Pharma Services Introduces AJICAP Bioconjugation Technology for ADC Manufacturing
PR-M12-18-NI-010
Expanded Capacity
Abzena’s New GMP Manufacturing Suite Expands ADC Chemistry Solutions at Bristol Site
PR-M03-18-NI-105
Capacity Expansion
Facility Expansion at Abzena
PTV-M06-17-BIO-017
ADC Conference
101 Antibody-Drug Conjugate Experts to Present at the Industry's Longest Standing & Most Comprehensive Antibody-Drug Conjugate Conference
PR-M09-17-NI-006
ADC
Pfizer Gets Second ADC Approval in 2017
PAO-M09-17-NI-019
Oncology
Telix and OBI License Abzena Cancer Fighters
PAO-M07-17-NI-029
Drug Delivery
The Future Of Uniquely Delivered Drugs and ADCs
MCP-M07-17-NI-020
ADC
Pfizer’s MYLOTARG Demonstrates Favorable Profile
PAO-M07-17-NI-022
Biopharmaceutical
Abzena on the Road to BIO: Fueling Biopharmaceutical Development
PTV-M06-17-CL-006
1
2
»
